InflaRx NV Quote - IFRX

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

2.42

Bid

2.01

Offer

3.50

Volume

178,129

2.44 Day's Range 2.64

1.165 52 Week Range 2.815

Market Cap

142.498M

Previous Close

2.55

Open

2.51

Last Trade

2.42

Last Trade Time

Financial Volume

US$ 455,632

VWAP

2.5579

Average Volume (3m)

292,601

Shares Outstanding

58,883,272

Dividend Yield

PE Ratio

-3.52

Earnings Per Share (EPS)

-0.72

Revenue

63k

Net Profit

-42.67M

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.inflarx.de

Headquarters

Jena, Deu

Founded

InflaRx NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IFRX. The last closing price for InflaRx NV was US$2.55. Over the last year, InflaRx NV shares have traded in a share price range of US$ 1.165 to US$ 2.815.

InflaRx NV currently has 58,883,272 shares in issue. The market capitalisation of InflaRx NV is US$150.15 million. InflaRx NV has a price to earnings ratio (PE ratio) of -3.52.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

InflaRx Announces Participation in January Events in San Francisco

JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the...

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.09	3.86266094421	2.33	2.65	2.16	146944	2.43638949	CS
4	0.34	16.3461538462	2.08	2.76	2.08	168209	2.46097134	CS
12	0.83	52.2012578616	1.59	2.815	1.48	292601	2.22273427	CS
26	0.76	45.7831325301	1.66	2.815	1.23	169155	2.05798722	CS
52	0.79	48.4662576687	1.63	2.815	1.165	179144	1.7876166	CS
156	-1.76	-42.1052631579	4.18	7.2499	0.7762	413152	3.74416634	CS
260	-1.32	-35.2941176471	3.74	9.7	0.7762	590519	4.23733541	CS

IFRX - Frequently Asked Questions (FAQ)

What is the current InflaRx NV share price?

The current share price of InflaRx NV is US$ 2.42

How many InflaRx NV shares are in issue?

InflaRx NV has 58,883,272 shares in issue

What is the market cap of InflaRx NV?

The market capitalisation of InflaRx NV is USD 150.15M

What is the 1 year trading range for InflaRx NV share price?

InflaRx NV has traded in the range of US$ 1.165 to US$ 2.815 during the past year

What is the PE ratio of InflaRx NV?

The price to earnings ratio of InflaRx NV is -3.52

What is the cash to sales ratio of InflaRx NV?

The cash to sales ratio of InflaRx NV is 2.32k

What is the reporting currency for InflaRx NV?

InflaRx NV reports financial results in EUR

What is the latest annual turnover for InflaRx NV?

The latest annual turnover of InflaRx NV is EUR 63k

What is the latest annual profit for InflaRx NV?

The latest annual profit of InflaRx NV is EUR -42.67M

What is the registered address of InflaRx NV?

The registered address for InflaRx NV is WINZERLAER, JENA, 07745

What is the InflaRx NV website address?

The website address for InflaRx NV is www.inflarx.de

Which industry sector does InflaRx NV operate in?

InflaRx NV operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BTCTBTC Digital Ltd	US$ 8.2697 (73.73%)	61.45M
BDMDBaird Medical Investment Holdings Ltd	US$ 8.80 (62.36%)	18.63M
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
NUKKNukkleus Inc	US$ 29.97 (45.98%)	19.09M
GSITGSI Technology	US$ 3.97 (44.36%)	87.7M
DOGZDogness International Corporation	US$ 18.23 (-58.77%)	740.45k
ORKTOrangeKloud Technology Inc	US$ 3.02 (-24.88%)	21.08M
PMAXPowell Max Ltd	US$ 0.6364 (-23.31%)	4.17M
LGCBLinkage Global Inc	US$ 0.2876 (-22.27%)	890.66k
YYAIConnexa Sports Technologies Inc	US$ 0.8299 (-20.20%)	602.48k
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
GCTKGlucoTrack Inc	US$ 0.0852 (15.45%)	465.22M
RIMEAlgorhythm Holdings Inc	US$ 0.0406 (-4.02%)	387.23M
TGLTreasure Global Inc	US$ 0.2459 (14.75%)	267.1M
NVDANVIDIA Corporation	US$ 137.71 (3.10%)	201.4M